Shattuck Labs, Inc. (STTK) · Nov 5, 2026 · Earnings

Shattuck Labs earnings miss as SL-325 Phase 2 advances

Miss — EPS $(0.14) vs approximately $(0.10) consensus; revenue $0 vs approximately $33K

Shattuck Labs’ Q3 earnings missed consensus, while SL-325 moves toward Phase 2 studies and cash remains sufficient into 2029.

Shattuck is a clinical-stage biotech shifting from early validation of its DR3 antibody platform into Phase 2 testing of SL-325, with Crohn’s disease and hidradenitis suppurativa now the main near-term development programs. The HS expansion and unchanged 2029 runway were already disclosed in October, so this filing mainly confirms execution rather than introducing a new strategic direction.

The quarter missed the modest financial benchmark. Shattuck reported a net loss of $0.14 per share versus a published estimate of approximately $0.10 loss, while revenue was zero against roughly $33,000 expected. The loss widened to $25.2 million from $10.1 million as research and development spending rose sharply with the company moving SL-325 and SL-846 further into development.

Q3 2026Q3 2025Consensus
Net loss (Income Statement)$25.2M$10.1M
Loss per share (Income Statement)$(0.14)$(0.14)$(0.10)
Revenue (Income Statement)$0$1.0M$0.033M
R&D expense (Income Statement)$21.6M$7.6M
Cash and short-term investments (Balance Sheet)$196.3M

The business program is advancing, but the milestones are mostly confirmation. Shattuck expects to initiate the approximately 150-patient RECEPTIVE-HS1 Phase 2 trial in HS during the fourth quarter of 2026, while Crohn’s Phase 2 induction data remain targeted for the first half of 2028. 〔0〕 The filing also points to initial Phase 1 data for SL-846 in 2027, but supplies no new clinical efficacy data that would materially change the investment case today.

Funding remains adequate for the current plan. Cash, cash equivalents, and short-term investments totaled $196.3 million at quarter-end, down from approximately $208.3 million at June 30, but management maintained its expectation of funding operations into 2029. 〔1〕 That runway supports the next development steps, though rising R&D expense shows the cost base is increasing as Phase 2 work begins.

Bottom line: This is a modest earnings miss against a low bar, partly offset by steady clinical execution and unchanged funding visibility. The filing reinforces Shattuck’s existing Phase 2 story rather than materially rewriting it.

What to watch next

RECEPTIVE-HS1 Phase 2 initiation, expected Q4 2026

Original filing on SEC EDGAR

More Shattuck Labs, Inc. news

Shattuck Labs earnings miss as SL-325 Phase 2 advances | STTK Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.